Other

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options

Vertex Pharmaceuticals Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options decreased by 50.0% to $27.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 61.7%, from $16.70M to $27.00M. Over 4 years (FY 2021 to FY 2025), Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options shows an upward trend with a 5.8% CAGR.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
Metric ID: other_proceeds_from_issuance_of_shares_under_incentive_a_319e60

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$37.90M$13.80M$34.70M$33.70M$64.40M$36.60M$51.60M$33.65M$33.65M$33.65M$33.65M$16.90M$55.00M$8.40M$34.30M$16.70M$49.10M$7.90M$54.00M$27.00M
QoQ Change—-63.6%+151.4%-2.9%+91.1%-43.2%+41.0%-34.8%+0.0%+0.0%+0.0%-49.8%+225.4%-84.7%+308.3%-51.3%+194.0%-83.9%+583.5%-50.0%
YoY Change————+69.9%+165.2%+48.7%-0.1%-47.7%-8.1%-34.8%-49.8%+63.4%-75.0%+1.9%-1.2%-10.7%-6.0%+57.4%+61.7%
Range$7.90M – $64.40M
CAGR-6.9%
Avg YoY Growth+14.7%
Median YoY Growth-0.7%

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options at Other Companies

ALN
Alnylam PharmaceuticalsALNYView metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Vertex Pharmaceuticals (VRTX) reported proceeds from issuance of shares under incentive and share based compensation plans including stock options of $27.00M in Q1 2026.
How has Vertex Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options changed year-over-year?
Vertex Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options increased by 61.7% year-over-year, from $16.70M to $27.00M.
What is the long-term trend for Vertex Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Over 4 years (2021 to 2025), Vertex Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options has grown at a 5.8% compound annual growth rate (CAGR), from $102.00M to $127.70M.